March 6, 2013
Progress on Antidote for Next-Generation Anti-Clotting Drugs
In the March 3, 2013, online edition of Nature Medicine, scientists from Portola Pharmaceuticals Inc. reported on its PRT064445, a recombinant and "ever so slightly engineered" version of Factor Xa that the company hopes will become a universal antidote to next-generation anti-clotting drugs.
To read the full article, visit: http://www.bioworld.com/content/progress-antidote-next-generation-anti-clotting-drugs
Available via subscription only.